CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/ Refractory B-cell Acute Lymphoblastic Leukemia
Purpose: Autologous chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed/refractory acute lymphocytic leukemia (r/r ALL). However, the use of autologous CAR-T cells with certain characteristics may delay the availability of therapy. Another problem caused by antigen escape after relapsed single-target CAR-T treatment. Therefore, we aim to develop CRISPR-edited universal off-the-shelf CD19/CD22 dual-targeting CAR-T cells as a novel therapy for the treatment of refractory ALL. PATIENTS AND METHODS: In this open-label, dose-escalation phase I study, a universal CD19/CD22-targeted CAR-T cell (CTA101) CRISPR/Cas9 disrupted the TRAC region and the CD52 gene to avoid host immune-mediated rejection was injected. /r All in the patient's body. Safety, efficacy, and CTA101 cell kinetics were assessed. Results: CRISPR/Cas9 technology mediates efficient, high-fidelity gene editing and production of universal CAR-T
Presentation
CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/ Refractory B-cell Acute Lymphoblastic Leukemia
1.0MB
Contact Us